Literature DB >> 8354915

Endemic human T cell leukemia virus type II infection in southwestern US Indians involves two prototype variants of virus.

B Hjelle1, S W Zhu, H Takahashi, S Ijichi, W W Hall.   

Abstract

Human T cell leukemia virus (HTLV) type II is endemic in certain American Indians, and high rates of infection occur in intravenous drug users (IVDUs). North American IVDUs are infected with two distinct variants, HTLV-IIa and -IIb. If IVDUs became infected as a result of interaction with members of an American Indian population, both viral forms should be demonstrable in such populations. Nucleotide sequence analysis of 630 bases of the env gene encoding the gp21 protein was done on DNA from 12 New Mexico Indians (8 Pueblo, 4 Navajo). All samples were typical subtype a or b viruses. Seven of the 8 Pueblo and 2 of 4 Navajo had subtype b; the rest had subtype a. The results are compatible with an indigenous New World origin for both subtypes of HTLV-II.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354915     DOI: 10.1093/infdis/168.3.737

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Molecular evidence for infection by HTLV-2 among individuals with negative serological screening tests for HTLV antibodies.

Authors:  R Ishak; A C R Vallinoto; V N Azevedo; A C P Vicente; W W Hall; M O G Ishak
Journal:  Epidemiol Infect       Date:  2006-09-07       Impact factor: 2.451

2.  Spontaneous cell proliferation is associated with poor sensitivity to glucocorticoids in patients infected with HTLV.

Authors:  R P Lopes; M Menna-Barreto; M E Bauer
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

3.  African origin of human T-lymphotropic virus type 2 (HTLV-2) supported by a potential new HTLV-2d subtype in Congolese Bambuti Efe Pygmies.

Authors:  A M Vandamme; M Salemi; M Van Brussel; H F Liu; K Van Laethem; M Van Ranst; L Michels; J Desmyter; P Goubau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 4.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

5.  Isolation and molecular characterization of a human T-cell lymphotropic virus type II (HTLV-II), subtype B, from a healthy Pygmy living in a remote area of Cameroon: an ancient origin for HTLV-II in Africa.

Authors:  A Gessain; P Mauclère; A Froment; M Biglione; J Y Le Hesran; F Tekaia; J Millan; G de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

6.  HTLV-II infection in the Western United States.

Authors:  B Hjelle
Journal:  West J Med       Date:  1994-06

7.  Different population dynamics of human T cell lymphotropic virus type II in intravenous drug users compared with endemically infected tribes.

Authors:  M Salemi; M Lewis; J F Egan; W W Hall; J Desmyter; A M Vandamme
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

8.  Identification and characterization of a new and distinct molecular subtype of human T-cell lymphotropic virus type 2.

Authors:  N Eiraku; P Novoa; M da Costa Ferreira; C Monken; R Ishak; O da Costa Ferreira; S W Zhu; R Lorenco; M Ishak; V Azvedo; J Guerreiro; M P de Oliveira; P Loureiro; N Hammerschlak; S Ijichi; W M Hall
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

9.  Prevalence of human T-cell lymphotropic virus types 1 and 2 in blood donors of the Caruaru Blood Center (Hemope).

Authors:  Waleska Mayara Gomes de Lima; Fabrício Andrade Martins Esteves; Maria do Carmo Morais Rodrigues Torres; Edna Suely Feitosa Pires
Journal:  Rev Bras Hematol Hemoter       Date:  2013

10.  Phylogenetic relationship and geographic distribution of multiple human T-cell lymphotropic virus type II subtypes.

Authors:  W M Switzer; D Pieniazek; P Swanson; H H Samdal; V Soriano; R F Khabbaz; J E Kaplan; R B Lal; W Heneine
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.